Valuation: Exelixis, Inc.

Market Cap 14.06B 12.32B 11.39B 10.47B 19.79B 1,355B 20.09B 136B 53.31B 663B 52.78B 51.63B 2,284B P/E 2026 *
17.6x
P/E 2027 * 15x
Enterprise Value 13.28B 11.64B 10.76B 9.89B 18.7B 1,281B 18.99B 128B 50.37B 626B 49.87B 48.78B 2,158B EV / Sales 2026 *
5.11x
EV / Sales 2027 * 4.21x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day-0.70%
1 week-1.72%
Current month+2.06%
1 month+6.97%
3 months+23.70%
6 months+26.32%
Current year+26.69%
1 week 54.39
Extreme 54.3928
56.75
1 month 50.8
Extreme 50.8
57.57
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 8.47
Extreme 8.4701
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
5/27/26 Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%-1.72%+24.87%+184.19% 14.06B
+0.21%-1.34%+53.17%+60.65% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-7.43%+4.35%+406.96% 23.48B
+0.74%+0.73%-16.23%-15.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-3.21%-0.19%+60.32%+147.14% 12.76B
Average +0.54%-1.88%+43.46%+177.82% 24.63B
Weighted average by Cap. +1.23%-2.06%+42.44%+141.17%

Financials

2026 *2027 *
Net sales 2.6B 2.28B 2.11B 1.94B 3.66B 251B 3.72B 25.15B 9.86B 123B 9.76B 9.55B 422B 2.93B 2.57B 2.37B 2.18B 4.13B 283B 4.19B 28.35B 11.11B 138B 11B 10.76B 476B
Net income 819M 717M 663M 610M 1.15B 78.95B 1.17B 7.92B 3.1B 38.59B 3.07B 3.01B 133B 945M 829M 766M 704M 1.33B 91.17B 1.35B 9.15B 3.59B 44.57B 3.55B 3.47B 154B
Net Debt -774M -678M -627M -576M -1.09B -74.61B -1.11B -7.48B -2.93B -36.48B -2.91B -2.84B -126B -1.72B -1.5B -1.39B -1.28B -2.42B -165B -2.45B -16.6B -6.51B -80.9B -6.44B -6.3B -279B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-07-20 $55.53 -0.70% 2,379,065
26-07-17 $55.92 +0.43% 2,555,561
26-07-16 $55.68 +0.23% 2,031,019
26-07-15 $55.55 -0.39% 1,895,909
26-07-14 $55.77 -0.48% 1,799,548
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
55.92USD
Average target price
50.93USD
Spread / Average Target
-8.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock